Portage Biotech Unveils Promising Data for PORT-7
Portage Biotech Inc. (NASDAQ: PRTG) has recently made significant strides in its clinical development, presenting groundbreaking preclinical results for its investigational treatment, PORT-7. This innovative selective Adenosine A2B receptor inhibitor was showcased by Dr. Luciano Mutti from the Gruppo Italiano Mesotelioma e Oncologia Ambientale at a major cancer congress in Europe. The data, revealed at the European Lung Cancer Congress, has garnered attention for demonstrating substantial tumor growth inhibition in preclinical models of mesothelioma.
Preclinical Highlights of PORT-7
The findings showed that PORT-7 exhibits impressive effects as a standalone treatment as well as in combination with an anti-PD1 antibody. In murine models, this combination achieved over 90% inhibition of tumor growth. Further examination through immunohistochemistry highlighted a marked infiltration of immune effector cells, essential for enhancing the body's anti-cancer response. This result signifies a promising avenue for treating mesothelioma, an aggressive cancer type that often encounters barriers due to immune resistance.
Exciting Plans for First-In-Human Trials
In light of these promising preclinical results, Portage Biotech is preparing to initiate its first-in-human clinical trial for PORT-7. The company aims to enter a new phase of enlightening research that could pave the way for effective therapies against mesothelioma. The clinical trials will seek to test the safety and efficacy of PORT-7 in human patients, potentially offering a much-needed alternative in a field where treatment options are scant.
Combining Innovations with PORT-6
Concurrently, Portage Biotech is advancing its other therapeutic, PORT-6, an established potent inhibitor of the A2A adenosine receptor. The company plans to combine PORT-6 with PORT-7 in an ongoing clinical trial. This pioneering approach marks the first time that two selective A2A and A2B receptor antagonists will be administered together in a clinical setting. The goal is to fully block adenosine-induced immunosuppression within the tumor microenvironment, aiming to boost anti-tumor responses and widen the spectrum of immunotherapy's effectiveness in solid tumors.
Portage Biotech: A Leader in Immuno-Oncology
Portage Biotech positions itself at the forefront of innovative cancer treatment strategies. The company is committed to advancing its pipeline of novel therapeutics aimed at transforming the immune system’s capacity to combat various cancers. As they approach significant milestones in their research, Portage's focus on developing therapies that harness the body's immune response illustrates their dedication to revolutionizing cancer care.
Contacting Portage Biotech
For those interested in further details about Portage Biotech's research and developments, the company encourages inquiries through their official contact channels. Alexander Pickett, the Chief Executive Officer, is available for queries, cementing the company's philosophy of transparency and engagement with the community.
Frequently Asked Questions
What is PORT-7?
PORT-7 is a selective Adenosine A2B receptor inhibitor being developed by Portage Biotech to target mesothelioma.
What were the results presented by Portage Biotech?
The preclinical results showed over 90% inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in murine models.
When will the first-in-human trials for PORT-7 begin?
Portage Biotech is preparing to commence its first-in-human clinical trials, although the exact timing is yet to be confirmed.
How does PORT-6 fit into Portage Biotech's strategy?
PORT-6 is an A2A receptor inhibitor that will be combined with PORT-7 in trials to enhance immunotherapy effectiveness against tumors.
Who can be contacted for more information about Portage Biotech?
For more information, inquiries can be directed to Alexander Pickett, CEO of Portage Biotech.
